Effects of development of host immunity on the biodistribution of xenogeneic MHC non-restricted cytotoxic T cells: Implications for adoptive cell therapy of cancer

International Journal of Oncology

Volumn 14, Issue 2, 1999, Pages 233-244

  Cesano, ALessandra ^a   Wortman, Jeffrey A ^b   Pourdehnad, Michael ^c   Visonneau, Sophie ^a   Mozley, David ^c   Bhatnagar, Anish ^c   Alavi, Abass ^c   Santoli, Daniela ^a  

^a WISTAR INSTITUTE   (United States)

^b UNIVERSITY OF PENNSYLVANIA SCHOOL OF VETERINARY MEDICINE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

111indium oxine; Biodistribution kinetics; Cytotoxic T cell trafficking; Immune responses

Indexed keywords

ADOPTIVE IMMUNOTHERAPY; ANIMAL; ARTICLE; CYTOTOXIC T LYMPHOCYTE; DOG; HUMAN; IMMUNITY; IMMUNOLOGY; MAJOR HISTOCOMPATIBILITY COMPLEX; TRANSPLANTATION; XENOGRAFT;

ANIMALS; DOGS; HUMANS; IMMUNITY; IMMUNOTHERAPY, ADOPTIVE; MAJOR HISTOCOMPATIBILITY COMPLEX; T-LYMPHOCYTES, CYTOTOXIC; TRANSPLANTATION, HETEROLOGOUS;

EID: 0033071025     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.14.2.233     Document Type: Article

References (9)

1. Haller O, Hansson M, Kiessling R and Wigzell H: Role of nonconventional natural killer cell resistance against syngeneic tumor cells in vivo. Nature 270: 609-611, 1977.
2. Hefeneider SH, Conlon PJ, Henney CS and Gillis S: In vivo interleukin-2 administration augments the generation of alloreactive cytolytic T lymphocytes and resident natural killer cells. J Immunol 130: 222-227, 1983.
3. Rosenberg SA: Immunotherapy of cancer by the systemic administration of lymphoid cells plus interleukin-2. J Biol Resp Mod 3: 501-511, 1984.
4. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG and White DE: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or hich dose interleukin-2 alone. N Engl J Med 316: 889-897, 1987.
5. Topalian SL, Solomon D, Avis FP, Chang AE, Frearksen DL, Linehan WM, Lotze MT, Robertson CN, Seipp CA, Simon P, Simpson CG and Rosenberg SA: Immunotherapy of patients with advanced cancer using tumor infiltrating lymphocytes and recombinant interleukin-2: a pilot study. J Clin Oncol 6: 839-853, 1988.
6. Itoh K, Tilden AB and Balch CM: Interleukin-2 activation of cytotoxic T lymphocytes infiltrating into human metastatic melanomas. Cancer Res 46: 3011-3017, 1986.
7. Topalian SL, Muul LM, Solomon D and Rosenberg SA: Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. J Immunol Methods 102: 127-141, 1987.
8. Cesano A and Santoli D: Two unique human leukemic T-cell lines endowed with stable cytotoxic function and different spectrum of target reactivity. Analysis and modulation of their lytic mechanisms. In Vitro Cell Dev Biol 28A: 648-656, 1992.
9. Cesano A and Santoli D: Inducible expression of granulocytemacrophage colony-stimulating factor, tumor necrosis factor-α, and interferon-γ in two human cytotoxic leukemic T cell lines. In Vitro Cell Dev Biol 28A: 657-662, 1992.